Alcohol Use Disorder - Pipeline Review, 2025

The global Alcohol Use Disorder pipeline has been expanding and evolving with the growing incidence of alcohol use addiction and working toward exploring new products for treatment of this disease.  Alcohol Use Disorder (AUD) is a commonly used term for alcoholism or alcohol addiction. This entails the failure to control drinking habits of an individual. AUD is a heterogeneous illness and has multifaceted biology. Controlled by several gene-by-environment interactions and genes, it is a severe form of alcohol abuse.

There are several effective and evidence-based treatments that now exist for treating and managing AUS. This therapeutics includes a number of pharmacotherapies to target specific aspects of biology that instigate and sustain dangerous alcohol exploitation. The reason for alcohol use disorder is not well understood. However, several factors are thought to contribute to its development. Therefore, various companies and academics are performing clinical research for assessing challenges and finding opportunities to influence AUD drug R&D activities for drug development. Various therapies are under development, focusing on improvement in treatment by novel approach.

Alcohol Use Disorder Pipeline Insights 2025: Report Scope

Covering 30+ companies and 30+ pipeline drugs, Fortune Business Insights has released its report “Alcohol Use Disorder Pipeline Insights 2025”. It presents an entire pipeline insight regarding clinical research and non-clinical stages of drug manufacturing and develops new treatments of Alcohol Use Disorder. This report also presents pipeline reviews, which includes phase 1, phase 2, and phase 3 trials of drug development and treatments. The drugs under development are on the basis of mechanism of action of the drugs, commercial assessment and clinical assessment. In addition, major regions of geography such as North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa are also covered in this report.

Reasons to Buy this Report

• Develop effective expansion strategies derived by complete overview of the R&D activity and Alcohol Use Disorder pipeline products for disease therapies.
• Identify competition and new companies in the market based on the pipeline products.
• Identify development plans to counteract the emergence of young players in the market.
• Identify the focus of R&D activities of top participants for Alcohol Use Disorder treatments.
• Identify possibilities of collaborations, acquisitions, and mergers based on licensing activities related to the treatment.
• Analyse the causes for inactive and discontinued products to propose changes in the R&D pivot, if required.

Know Answers to Your Questions

• How many companies are making Alcohol Use Disorder drugs?
• How many Alcohol Use Disorder drugs are manufactured by each company?
• How many novel drugs are in phase 2 trials and phase 3 trials of development for the treatment of Alcohol Use Disorder?
• What are the key alliances (Industry–Industry, Industry–Academia), mergers and acquisitions, licensing activities associated with the Alcohol Use Disorder therapeutics?
• What are the current trends, drug types, and innovative technologies developed to rise above the limitation of existing therapies?
• What are the clinical studies happening for Alcohol Use Disorder and their status?
• What are the key authorizations that have been granted to emerging drugs?

Report Methodology

• These pipeline reports are created by the assessment of several data that is mainly collected from credible desk research sources. In addition, secondary data has also been collected that is supplemented by conducting interviews with expert opinion leaders.
• The desk research sources include press releases and investor presentations of companies and annual reports, white papers, websites, news articles. These sources also comprise databases from global and regional clinical trials, industrial associations published reports, as well as articles/reports published on databases from NCBI, internal databases, and ResearchGate.

Clinical Trial Insights

The rising emphasis on requirement for needed drugs and effective therapies for lung disease prevention and cure are impelling the demand for the development of drug pipelines which is pushing R&D activities. There are numerous healthcare institutes, players connected with the medical sectors, and diverse research organizations are conducting clinical trials for developing new drugs for treatment of Alcohol Use Disorder. Government bodies have increased emphasis on improving infrastructure for healthcares supporting the worldwide clinical trials scenario in the field of Alcohol Use Disorder treatment.

Alcohol Use Disorder Pipeline Overview

Escalating awareness activities and encouraging government policies has encouraged development initiatives for products. Diverse new drug candidates are under preclinical as well as discovery stages along with their Phase 1, Phase 2, and Phase 3 trials. There are additional developments in the market comprising collaborations, mergers, and licensing as well as systematic therapeutic assessment for emerging drugs. Key healthcare organizations are also keen to look for drug approvals from regulatory bodies to bring candidates to the market.

A brief coverage of Alcohol Use Disorder emerging drug in pipeline:

AD04: Adial Pharmaceuticals

AD04 is a genetically targeted therapeutic agent designed for treating AUD (Alcohol Use Disorder). It is developed by Adial Pharmaceuticals. It works through the modulation of specific neurotransmitter pathways in the brain's reward and support circuits associated with alcohol consumption. The drug is being developed for patients with particular genetic markers, acknowledged through a proprietary companion diagnostic genetic test and has shown assurance in dropping heavy drinking days in a subgroup of patients in a Phase 3 trial.

Sunobinop: Imbrium Therapeutics

Sunobinop is designed to bind to and activate the nociceptin/orphanin-FQ peptide receptor (NOP). This drug candidate is a novel, investigational, and probably first-in-class oral compound. Presently, the drug is in the Phase 2 trial stage of its clinical trial for the healing of AUD.

BICX104: BiocorRx Pharmaceuticals

BioCorRx Pharmaceuticals Inc is developing BICX104 to improve patient compliance to naltrexone therapy when compared with other treatments in the market. This is a long-acting and biodegradable subcutaneous pellet of naltrexone for treating OUD (opioid use disorder). This drug candidate is in the Phase 1 trial stage for the treatment of AUD.